Cargando…

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer

Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan. Patients who receive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Noriko, Matsuo, Yukinori, Shintani, Takashi, Ogura, Masakazu, Mitsuyoshi, Takamasa, Araki, Norio, Fujii, Kota, Okumura, Setsuko, Nakamatsu, Kiyoshi, Kishi, Takahiro, Atsuta, Tomoko, Sakamoto, Takashi, Ohtsu, Shuji, Katagiri, Tomohiro, Narabayashi, Masaru, Fujishiro, Satsuki, Iizuka, Yusuke, Ozasa, Hiroaki, Hirai, Toyohiro, Mizowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855316/
https://www.ncbi.nlm.nih.gov/pubmed/36149029
http://dx.doi.org/10.1093/jrr/rrac057
_version_ 1784873349037424640
author Kishi, Noriko
Matsuo, Yukinori
Shintani, Takashi
Ogura, Masakazu
Mitsuyoshi, Takamasa
Araki, Norio
Fujii, Kota
Okumura, Setsuko
Nakamatsu, Kiyoshi
Kishi, Takahiro
Atsuta, Tomoko
Sakamoto, Takashi
Ohtsu, Shuji
Katagiri, Tomohiro
Narabayashi, Masaru
Fujishiro, Satsuki
Iizuka, Yusuke
Ozasa, Hiroaki
Hirai, Toyohiro
Mizowaki, Takashi
author_facet Kishi, Noriko
Matsuo, Yukinori
Shintani, Takashi
Ogura, Masakazu
Mitsuyoshi, Takamasa
Araki, Norio
Fujii, Kota
Okumura, Setsuko
Nakamatsu, Kiyoshi
Kishi, Takahiro
Atsuta, Tomoko
Sakamoto, Takashi
Ohtsu, Shuji
Katagiri, Tomohiro
Narabayashi, Masaru
Fujishiro, Satsuki
Iizuka, Yusuke
Ozasa, Hiroaki
Hirai, Toyohiro
Mizowaki, Takashi
author_sort Kishi, Noriko
collection PubMed
description Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan. Patients who received CCRT for stage III NSCLC were included in this study. Of 178 eligible patients, 136 were in the CCRT+D and 42 were in the CCRT cohorts. Locoregional recurrence (LR), LR plus distant metastases (DM), and DM were observed in 20.6%, 8.8%, 27.9% of the CCRT+D, and 26.2%, 16.7% and 33.3% of the CCRT cohorts, respectively. In-field recurrence was the most common LR pattern in both cohorts. Squamous cell carcinoma and PD-L1 expression < 1%, and female sex and EGFR mutations were significantly associated with an increased risk of LR and DM. In patients with any risk factors for LR, the incidence of LR was similar in the CCRT+D and CCRT (39.5% vs 45.5%). The 24 month progression-free survival (PFS) and overall survival (OS) were 40.3% and 69.4% in the CCRT+D and 24.7% and 61.0% in the CCRT cohorts, respectively. Poor performance status and no consolidation durvalumab were significantly associated with shorter PFS. There was a significant difference in PFS between the CCRT+D and CCRT in the propensity score-matched cohort (HR = 0.51, P = 0.005). In conclusion, consolidation durvalumab decreased both LR and DM, and significantly improved PFS. However, in-field recurrence was still a major problem, as well as DM.
format Online
Article
Text
id pubmed-9855316
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98553162023-01-23 Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer Kishi, Noriko Matsuo, Yukinori Shintani, Takashi Ogura, Masakazu Mitsuyoshi, Takamasa Araki, Norio Fujii, Kota Okumura, Setsuko Nakamatsu, Kiyoshi Kishi, Takahiro Atsuta, Tomoko Sakamoto, Takashi Ohtsu, Shuji Katagiri, Tomohiro Narabayashi, Masaru Fujishiro, Satsuki Iizuka, Yusuke Ozasa, Hiroaki Hirai, Toyohiro Mizowaki, Takashi J Radiat Res Regular paper Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan. Patients who received CCRT for stage III NSCLC were included in this study. Of 178 eligible patients, 136 were in the CCRT+D and 42 were in the CCRT cohorts. Locoregional recurrence (LR), LR plus distant metastases (DM), and DM were observed in 20.6%, 8.8%, 27.9% of the CCRT+D, and 26.2%, 16.7% and 33.3% of the CCRT cohorts, respectively. In-field recurrence was the most common LR pattern in both cohorts. Squamous cell carcinoma and PD-L1 expression < 1%, and female sex and EGFR mutations were significantly associated with an increased risk of LR and DM. In patients with any risk factors for LR, the incidence of LR was similar in the CCRT+D and CCRT (39.5% vs 45.5%). The 24 month progression-free survival (PFS) and overall survival (OS) were 40.3% and 69.4% in the CCRT+D and 24.7% and 61.0% in the CCRT cohorts, respectively. Poor performance status and no consolidation durvalumab were significantly associated with shorter PFS. There was a significant difference in PFS between the CCRT+D and CCRT in the propensity score-matched cohort (HR = 0.51, P = 0.005). In conclusion, consolidation durvalumab decreased both LR and DM, and significantly improved PFS. However, in-field recurrence was still a major problem, as well as DM. Oxford University Press 2022-09-22 /pmc/articles/PMC9855316/ /pubmed/36149029 http://dx.doi.org/10.1093/jrr/rrac057 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular paper
Kishi, Noriko
Matsuo, Yukinori
Shintani, Takashi
Ogura, Masakazu
Mitsuyoshi, Takamasa
Araki, Norio
Fujii, Kota
Okumura, Setsuko
Nakamatsu, Kiyoshi
Kishi, Takahiro
Atsuta, Tomoko
Sakamoto, Takashi
Ohtsu, Shuji
Katagiri, Tomohiro
Narabayashi, Masaru
Fujishiro, Satsuki
Iizuka, Yusuke
Ozasa, Hiroaki
Hirai, Toyohiro
Mizowaki, Takashi
Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title_full Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title_fullStr Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title_full_unstemmed Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title_short Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
title_sort recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage iii non-small cell lung cancer
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855316/
https://www.ncbi.nlm.nih.gov/pubmed/36149029
http://dx.doi.org/10.1093/jrr/rrac057
work_keys_str_mv AT kishinoriko recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT matsuoyukinori recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT shintanitakashi recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT oguramasakazu recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT mitsuyoshitakamasa recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT arakinorio recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT fujiikota recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT okumurasetsuko recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT nakamatsukiyoshi recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT kishitakahiro recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT atsutatomoko recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT sakamototakashi recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT ohtsushuji recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT katagiritomohiro recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT narabayashimasaru recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT fujishirosatsuki recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT iizukayusuke recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT ozasahiroaki recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT hiraitoyohiro recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT mizowakitakashi recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer
AT recurrencepatternsandprogressionfreesurvivalafterchemoradiotherapywithorwithoutconsolidationdurvalumabforstageiiinonsmallcelllungcancer